A Scientific Turning Point In The Treatment Of Cancer: The Kiss Of Death!


Scientists have succeeded in killing proteins they could not remove with a new method called 'kiss of death.' This has been a big turning point in cancer treatment. The developments, which we have compiled the details of from the Huffington Post, has excited the medical world.

Source: http://www.huffingtonpost.co.uk/entry/sc...

For a long time, researchers have known about the vital role that proteins play in spreading cancerous tumors around the human body.


But they were unable to halt them in their tracks. 

Professor Alessio Ciulli explained: “We know of many proteins which are active in causing diseases, but which we have been unable to block from going rogue or to stop them when they do.”

Now the team at the University of Dundee has found a way to neutralize these stubborn proteins, which had previously been deemed untouchable by drugs.


The process works by introducing small molecules to target these bad proteins, that then bind to them, neutralize them, and start a chain of events that degrades them and breaks them down in the body.

However, in the past, the major stumbling block has been finding the molecules that would work to bind and at the same time hamper functionality. As proteins can often fool regulators within the cell and can be difficult to pin down.

So instead of using these small molecules to locate and disable the protein, the new study, is working on a way to attract the neutralizing proteins, which then bind to the bad neighbor and act against it.


Ciulli said: “Crucially, we have also found that it is not enough for this neutralizing protein to sit close to the bad protein, it has to make direct contact with it, to `kiss’ it.

"And not just a little peck, but a real `Gone With The Wind’ embrace. We call this a ‘kiss of death,’ as it is the key to ensure the degradation of the bad protein.”


The work focused on pairing one of the BET bromodomain proteins, BRD4, which is an attractive drug target for cancer, with a selective BRD4 degrader called MZ1.  

“The road to turning degraders into drugs will be long and winding and we cannot get there on our own. It is exciting to see signs of serious commitment from the pharmaceutical industry,” said Ciulli.

How do you feel?
Tears of Joy
Relieved Face
Clapping Hands
Thumbs Down
Send Feedback